We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Regeneron (REGN) Disappoint Investors in Q4 Earnings?
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is scheduled to release fourth-quarter 2017 results on Feb 8, before the opening bell.
Last quarter, Regeneron beat earnings expectations by 1.53%. The company’s performance has been mixed so far. In the last four quarters, it surpassed earnings estimates on two occasions and missed in two, with an average positive surprise of 5.96%. Let’s see how things are shaping up for this quarter.
Regeneron’s stock has lost 3.9% in the last 12 months as against the industry’s gain of 3.8%.
Factors Influencing This Quarter
Regeneron’s key growth driver, Eylea, is likely to continue to contribute to the company’s top-line growth. In January 2018, the company stated Eylea net sales were approximately $3.7 billion in the United States in 2017 and expects $2 billion of sales from outside the United States.
We note that Regeneron has a global development and commercialization agreement with Bayer AG (BAYRY - Free Report) outside the United States for Eylea. Product revenues from ex-U.S. Eylea sales are recorded by Bayer.
Meanwhile, Regeneron is working on expanding Eylea label into additional indications. While a phase III study (PANORAMA) is evaluating Eylea for the treatment of moderately severe to severe non-proliferative diabetic retinopathy in patients without DME, another phase III study (in Japan) is evaluating it for neovascular glaucoma. Label expansion into additional indications would give Eylea access to higher patient population and increase the commercial potential of the drug. The FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for the label expansion of Eylea Injection. The company is seeking approval for a 12-week dosing interval of Eylea Injection in patients with wet age-related macular degeneration based on physician's assessment. The action date set by the FDA is Aug 11, 2018.
Apart from Eylea, investors will remain focused on the uptake of new drugs — Kevzara and Dupixent. Kevzara (sarilumab), an anti interleukin (IL)-6 receptor monoclonal antibody was approved in Canada for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response to or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs and was approved by the FDA in May 2017.
The FDA also approved Dupixent (dupilumab) Injection for the treatment of adults with moderate-to-severe atopic dermatitis. The initial uptake of the drug is encouraging. The drug was approved in Europe also. The company is also evaluating the drug for treating asthma in adults (LIBERTY ASTHMA QUEST study). A phase III study of Dupixent in pediatric patients (6-11 years of age) with uncontrolled persistent asthma was initiated in second-quarter 2017 an sBLA has been submitted to the FDA.
Hence, focus will be on the company’s performance, particularly Eylea and Dupixient uptake during the fourth-quarter earnings call. Investors are also expected to await updates on the company’s pipeline.
Meanwhile, Regeneron and partner Sanofi (SNY - Free Report) have been allowed to continue to sell their PCSK9 inhibitor, Praluent, in the United States by the Court of Appeals for the Federal Circuit following a favorable ruling. This bodes well and we expect the management to throw more light on the upside if any. However, sales of the drug have failed to impress so far. The company expects top-line data from ODYSSEY OUTCOMES in first-quarter 2018.
We expect investors to keep an eye on pipeline updates as well.
Earnings Whispers
Our proven model does not conclusively show that Regeneron is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -1.04%. This is because both the Most Accurate estimate is $4.63 while the Zacks Consensus Estimate is $4.68. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Regeneron currently carries a Zacks Rank #4 (Sell). Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) before going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise
Here is a health care stock that you may want to consider instead, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Will Regeneron (REGN) Disappoint Investors in Q4 Earnings?
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is scheduled to release fourth-quarter 2017 results on Feb 8, before the opening bell.
Last quarter, Regeneron beat earnings expectations by 1.53%. The company’s performance has been mixed so far. In the last four quarters, it surpassed earnings estimates on two occasions and missed in two, with an average positive surprise of 5.96%. Let’s see how things are shaping up for this quarter.
Regeneron’s stock has lost 3.9% in the last 12 months as against the industry’s gain of 3.8%.
Factors Influencing This Quarter
Regeneron’s key growth driver, Eylea, is likely to continue to contribute to the company’s top-line growth. In January 2018, the company stated Eylea net sales were approximately $3.7 billion in the United States in 2017 and expects $2 billion of sales from outside the United States.
We note that Regeneron has a global development and commercialization agreement with Bayer AG (BAYRY - Free Report) outside the United States for Eylea. Product revenues from ex-U.S. Eylea sales are recorded by Bayer.
Meanwhile, Regeneron is working on expanding Eylea label into additional indications. While a phase III study (PANORAMA) is evaluating Eylea for the treatment of moderately severe to severe non-proliferative diabetic retinopathy in patients without DME, another phase III study (in Japan) is evaluating it for neovascular glaucoma. Label expansion into additional indications would give Eylea access to higher patient population and increase the commercial potential of the drug. The FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for the label expansion of Eylea Injection. The company is seeking approval for a 12-week dosing interval of Eylea Injection in patients with wet age-related macular degeneration based on physician's assessment. The action date set by the FDA is Aug 11, 2018.
Apart from Eylea, investors will remain focused on the uptake of new drugs — Kevzara and Dupixent. Kevzara (sarilumab), an anti interleukin (IL)-6 receptor monoclonal antibody was approved in Canada for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response to or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs and was approved by the FDA in May 2017.
The FDA also approved Dupixent (dupilumab) Injection for the treatment of adults with moderate-to-severe atopic dermatitis. The initial uptake of the drug is encouraging. The drug was approved in Europe also. The company is also evaluating the drug for treating asthma in adults (LIBERTY ASTHMA QUEST study). A phase III study of Dupixent in pediatric patients (6-11 years of age) with uncontrolled persistent asthma was initiated in second-quarter 2017 an sBLA has been submitted to the FDA.
Hence, focus will be on the company’s performance, particularly Eylea and Dupixient uptake during the fourth-quarter earnings call. Investors are also expected to await updates on the company’s pipeline.
Meanwhile, Regeneron and partner Sanofi (SNY - Free Report) have been allowed to continue to sell their PCSK9 inhibitor, Praluent, in the United States by the Court of Appeals for the Federal Circuit following a favorable ruling. This bodes well and we expect the management to throw more light on the upside if any. However, sales of the drug have failed to impress so far. The company expects top-line data from ODYSSEY OUTCOMES in first-quarter 2018.
We expect investors to keep an eye on pipeline updates as well.
Earnings Whispers
Our proven model does not conclusively show that Regeneron is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -1.04%. This is because both the Most Accurate estimate is $4.63 while the Zacks Consensus Estimate is $4.68. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Regeneron currently carries a Zacks Rank #4 (Sell). Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) before going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise | Regeneron Pharmaceuticals, Inc. Quote
Stock That Warrants a Look
Here is a health care stock that you may want to consider instead, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Anthera Pharmaceuticals (ANTH - Free Report) is expected to release fourth-quarter results on Feb 26. The company has an Earnings ESP of +20.47% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>